Nov 3rd, 2019 - The guidelines on preventing secondary fractures in persons aged 65 years or older with a hip or vertebral fracture were released on September 20, 2019, by the American Society for Bone and Mineral Research (ASBMR). Fundamental Recommendations Communicate the following three simple messages to people aged 65 years or older with a hip or vertebral fracture (as well as to their family/caregive...
Oct 7th, 2019 - ORLANDO, Florida — New consensus guidelines on the prevention of secondary fractures from a coalition of bone health experts, professional organizations, and patient advocacy groups provide comprehensive recommendations on the course of clinical care after hip or vertebral fracture in people aged 65 years and older, emphasizing treatment, communication, and multidisciplinary care interventions....
May 19th, 2019 - In the wake of research that uncovered high levels of contamination in "sterile" implants, researchers are calling for the elimination of rewashing and resterilizing of pedicle screws in spinal fusion surgery. These researchers, including the president of the North American Spine Society, Jeffrey C. Wang, MD, and other leaders in the field, believe that intraoperatively guarded, presterilized, ...
May 1st, 2019 - Long-term use of alendronate and zoledronic acid for more than 3 years reduces the rate of vertebral fracture in treatment-naive postmenopausal women with notable, yet rare, adverse events, but too little evidence exists to make determinations on the long-term benefit/risk profile of other bisphosphonates or other osteoporosis drugs besides raloxifene and oral hormone therapy, according to a re.
MDedge Family Medicine;
Apr 4th, 2019 - Hip and vertebral fracture riskis associated with PPIs A 2011 systematic review and meta-analysis investigated the risk of fracture in adult patients taking PPIs for any indication. 4 The analysis included 10 observational studies (4 cohort, 6 case-control) with a total of 223,210 fracture cases.
Jan 24th, 2019 - "Routine use of vertebral augmentation for pain relief after vertebral fracture is not supported by current data," a new report commissioned by the American Society for Bone and Mineral Research (ASBMR) concludes. The report, with lead author Peter R. Ebeling, MBBS, Monash University, Clayton, Australia, was published online January 24 in the Journal of Bone and Mineral Research. The most commo...
Dec 5th, 2018 - Age also is a key factor in fracture risk assessment Gourlay and colleagues more recently conducted a retrospective analysis of new occurrence of treatment-level fracture risk scores in postmenopausal women (50 years of age and older) before they received pharmacologic treatment and before they experienced a first hip or clinical vertebral fracture. In 54,280 postmenopausal women aged 50 to 64.
Oct 9th, 2018 - Laura Beil is a health and science writer who won the 2018 Victor Cohn Prize for Excellence in Medical Science Reporting from the Council for the Advancement of Science Writing. Laura Beil One of her latest projects, Dr. Death, is an incredibly popular six-part podcast from Wondery that explores the case of Christopher Duntsch. The neurosurgeon is alleged to have injured 33 patients and was con...
Oct 8th, 2018 - Ensuring that older adults who have experienced a hip or vertebral fracture understand they likely have osteoporosis, and offering prompt drug treatment for the condition, are among five fundamental recommendations put together by a coalition of U. S.
Sep 30th, 2018 - The U. S.
Mary Ellen Schneider
Apr 25th, 2018 - The drugmaker Epizyme has temporarily halted U. S.
Apr 25th, 2018 - The US Food and Drug Administration (FDA) has placed a partial hold on clinical trials of tazemetostat, an EZH2 inhibitor being developed to treat solid tumors and lymphomas. The hold has halted enrollment in US-based trials of tazemetostat, but study subjects who have not experienced disease progression may continue to receive the drug.
Jan 13th, 2018 - A recent JAMA meta-analysis of 33 clinical trials and 51,145 participants showed that calcium, vitamin D, or both affords no decreased risk of hip fractures compared with placebo or no treatment. The authors performed a systematic literature review of data from published randomized trials, performed from July 16, 2012, to July 16, 2017. The primary outcome of interest was hip fracture and secon...
Dec 7th, 2017 - WASHINGTON (Reuters) - Josh Brookhart has four health insurers to choose from in Seattle’s King County for 2018, more than many Americans like him who buy coverage on the Obamacare individual market. Yet none of the plans cover all the complex medical care needed for his seven-year-old son, Gabriel. Born with an extreme form of Chiari malformation, Gabriel required surgery to reinsert a part of...
Dec 3rd, 2017 - NEW YORK (Reuters Health) - A novel locus on chromosome 2 is associated with clinical vertebral fractures independently of bone density, according to results from a genome-wide association study (GWAS). Clinical vertebral fractures are associated with an increased risk of future fractures and increased mortality. A previous GWAS failed to identify significant genetic predictors of radiographic ...
Sep 22nd, 2017 - DENVER – The anabolic agent teriparatide reduced the risk of clinical vertebral fractures in women with osteoporosis when compared with the antiresorptive agent risedronate, and the results held up across groups of women with varying fracture histories in a post hoc analysis of data from the VERO trial. VERO, which pitted teriparatide (Forteo) against risedronate in women with at least two mode.
Sep 12th, 2017 - DENVER — Final results of the phase 3 Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) study show encouraging benefits of the anabolic drug romosozumab (Amgen) followed by alendronate in reducing the risk of vertebral and clinical fracture and rapidly improving bone-mineral density (BMD) in high risk patients with osteoporosis. "We found that bone-f...
Michele G. Sullivan
Jun 15th, 2017 - MADRID – Romosozumab, an investigational bone-building agent, reduced new vertebral fractures by 73% among postmenopausal women with osteoporosis. Compared with placebo, the monoclonal antibody also reduced the risk of a clinical fracture by 36% after 12 months of treatment, Piet Geusens, MD, said at the European Congress of Rheumatology.
Sep 18th, 2016 - ATLANTA — Romosozumab (Amgen/UCB Pharma), an investigational monoclonal antibody that increases bone formation and decreases bone resorption, reduces vertebral fracture rates by 73% compared with placebo at the end of 1 year. There was also a further reduction in vertebral fracture risk in the second year following transition to the antiresorptive drug denosumab (Prolia, Amgen) in the phase 3 r...
Apr 11th, 2016 - Patient-controlled epidural analgesia achieves pain control similar to that of patient-controlled intravenous analgesia after spinal fusion surgery, but is associated with a higher incidence of pruritus and paresthesia, a meta-analysis published in BMC Musculoskeletal Disorders has found. The analysis of eight randomized controlled trials involving 482 patients found that patient-controlled epi.